Electromedical Technologies R&D Spending Growth & History (EMED)
Electromedical Technologies's r&d spending was $231,434 for fiscal 2023.
View full Electromedical Technologies company overviewElectromedical Technologies annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | $231,434 | $139,135 | +150.74% |
| 2022 | 2022-12-31 | $92,299 | −$123,021 | −57.13% |
| 2021 | 2021-12-31 | $215,320 | $183,720 | +581.39% |
| 2020 | 2020-12-31 | $31,600 | −$51,249 | −61.86% |
| 2019 | 2019-12-31 | $82,849 | — | — |
Electromedical Technologies quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2020 | 2020-09-30 | $0 | −$14,529 | — |
| Q2 2020 | 2020-06-30 | $4,000 | −$17,081 | −81.03% |
| Q3 2019 | 2019-09-30 | $14,529 | — | — |
| Q2 2019 | 2019-06-30 | $21,081 | — | — |
Electromedical Technologies r&d spending trends
Between the periods ended 2019-12-31 and 2023-12-31, Electromedical Technologies's r&d spending increased from $82,849 to $231,434, a change of $148,585. The latest reported quarter, Q3 2020, shows $0.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Electromedical Technologies source filings ↗